Predict your next investment

HEALTHCARE | Drug Development
osmotica.com

See what CB Insights has to offer

Founded Year

2000

Stage

IPO | IPO

Total Raised

$190M

Date of IPO

10/18/2018

About Osmotica

Osmotica is a global specialty pharmaceutical company which uses its osmotic technology platform to develop and commercialize pharmaceutical products. In addition to the products currently on the market, the company's pipeline includes numerous ANDA programs and several innovative neurology-based NDA programs.

Osmotica Headquarter Location

400 Crossing Boulevard

Bridgewater, New Jersey, 08807,

United States

770-509-4500

Latest Osmotica News

Osmotica Pharmaceuticals (OSMT) Reports Q3 Loss, Misses Revenue Estimates

Nov 16, 2021

Osmotica Pharmaceuticals (OSMT) delivered earnings and revenue surprises of -16.67% and -7.96%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the... This story originally appeared on Zacks Osmotica Pharmaceuticals (OSMT) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items. - Zacks This quarterly report represents an earnings surprise of -16.67%. A quarter ago, it was expected that this company would post a loss of $0.15 per share when it actually produced a loss of $0.15, delivering no surprise. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Osmotica Pharmaceuticals, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $2.2 million for the quarter ended September 2021, missing the Zacks Consensus Estimate by 7.96%. This compares to year-ago revenues of $57.17 million. The company has not been able to beat consensus revenue estimates over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Osmotica Pharmaceuticals shares have lost about 52.2% since the beginning of the year versus the S&P 500's gain of 24.7%. What's Next for Osmotica Pharmaceuticals? While Osmotica Pharmaceuticals has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Osmotica Pharmaceuticals was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.28 on $4.26 million in revenues for the coming quarter and -$1.18 on $19.12 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Osmotica

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Osmotica is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Osmotica Patents

Osmotica has filed 41 patents.

The 3 most popular patent topics include:

  • Dosage forms
  • Drug delivery devices
  • Amines
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/24/2020

8/17/2021

Dosage forms, Drug delivery devices, Calcium channel blockers, Amines, Pharmacokinetics

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

2/24/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

8/17/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Dosage forms, Drug delivery devices, Calcium channel blockers, Amines, Pharmacokinetics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Osmotica Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Osmotica Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.